

# Basic Drug List Updates

July 2025

TRADE NAME (generic name)	Brand/Generic Product	Description of Change
ADALIMUMAB-ADAZ (adalimumab-adaz soln auto-injector 80 mg/0.8ml)	Brand	Addition, Preferred Status
ADALIMUMAB-ADAZ (adalimumab-adaz soln prefilled syringe 10 mg/0.1ml)	Brand	Addition, Preferred Status
ADALIMUMAB-ADAZ (adalimumab-adaz soln prefilled syringe 20 mg/0.2ml)	Brand	Addition, Preferred Status
ATTRUBY (acoramidis hcl tab pack 356 mg (712 mg twice daily))	Brand	Addition, Preferred Status
CTEXLI (chenodiol tab 250 mg)	Brand	Addition, Preferred Status
EBGLYSS (lebrikizumab-lbkz solution prefilled syringe 250 mg/2ml)	Brand	Addition, Preferred Status
EBGLYSS (lebrikizumab-lbkz subcutaneous soln auto-inject 250 mg/2ml)	Brand	Addition, Preferred Status
ESPEROCT (antihemophilic factor recomb glycopeg-exei for inj 4000 unit)	Brand	Addition, Preferred Status
ITOVEBI (inavolisib tab 3 mg)	Brand	Addition, Preferred Status
ITOVEBI (inavolisib tab 9 mg)	Brand	Addition, Preferred Status
JIVI (antihemophil fact rcmb (bdd-rfviii peg-aucl)for inj 4000 unit)	Brand	Addition, Preferred Status
MESNEX (mesna tab 400 mg)	Brand	Removal, Non-Preferred Status, generics available
NEMLUVIO (nemolizumab-ilto for subcutaneous auto-injector 30 mg)	Brand	Addition, Preferred Status
NEXIUM (esomeprazole magnesium for delayed release susp pack 2.5 mg)	Brand	Removal, Non-Preferred Status, generics available
NEXIUM (esomeprazole magnesium for delayed release susp packet 5 mg)	Brand	Removal, Non-Preferred Status, generics available
SELARSDI (ustekinumab-aekn soln prefilled syringe 45 mg/0.5ml)	Brand	Addition, Preferred Status
SELARSDI (ustekinumab-aekn soln prefilled syringe 90 mg/ml)	Brand	Addition, Preferred Status
SIMLANDI (adalimumab-ryvk prefilled syringe kit 20 mg/0.2ml)	Brand	Addition, Preferred Status
SIMLANDI (adalimumab-ryvk prefilled syringe kit 80 mg/0.8ml)	Brand	Addition, Preferred Status
SIMLANDI 1-PEN KIT (adalimumab-ryvk auto-injector kit 80 mg/0.8ml)	Brand	Addition, Preferred Status
STEQEYMA (ustekinumab-stba soln prefilled syringe 45 mg/0.5ml)	Brand	Addition, Preferred Status
STEQEYMA (ustekinumab-stba soln prefilled syringe 90 mg/ml)	Brand	Addition, Preferred Status
TREMFYA INDUCTION PACK FOR CROHNS DISEASE (guselkumab soln auto-injector 200 mg/2ml)	Brand	Addition, Preferred Status
TREMFYA PEN (guselkumab soln auto-injector 100 mg/ml)	Brand	Addition, Preferred Status
VELPHORO (sucroferric oxyhydroxide chew tab 500 mg)	Brand	Removal, Non-Preferred Status
YESINTEK (ustekinumab-kfce soln prefilled syringe 45 mg/0.5ml)	Brand	Addition, Preferred Status
YESINTEK (ustekinumab-kfce soln prefilled syringe 90 mg/ml)	Brand	Addition, Preferred Status
YESINTEK (ustekinumab-kfce subcutaneous soln 45 mg/0.5ml)	Brand	Addition, Preferred Status

Blue Cross and Blue Shield of Illinois (BCBSIL), Blue Cross and Blue Shield of Montana (BCBSMT), Blue Cross and Blue Shield of New Mexico (BCBSNM), Blue Cross and Blue Shield of Oklahoma (BCBSOK), and Blue Cross and Blue Shield of Texas (BCBSTX) are Divisions of Health Care Service Corporation, a Mutual Legal Reserve Company, an Independent Licensee of the Blue Cross Blue Shield Association. BCBSIL, BCBSMT, BCBSNM, BCBSOK, and BCBSTX contract with Prime Therapeutics to provide pharmacy benefit management and related other services. BCBSIL, BCBSMT, BCBSNM, BCBSOK, and BCBSTX, as well as several independent Blue Cross and Blue Shield Plans, have an ownership interest in Prime Therapeutics LLC.